Login to Your Account



FDA Panel Appears To Support Genzyme's BLA For Fabry Drug

By Kim Coghill


Tuesday, January 14, 2003
BETHESDA, Md. - An FDA panel on Monday said Genzyme General's surrogate endpoint from its Phase III trial of Fabrazyme in Fabry disease patients is likely to predict a clinically meaningful effect. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription